NINDS U01 Clinical Trial Renewal Guide
Updated 5 official sources
Quick Answer: PAR-25-149 NINDS U01 renewal eligibility turns on 7 checks: existing eligible U01 award, same approved clinical trial, no new aims, remaining milestone proof, clinical-trial reporting, cooperative-agreement oversight, and due-date readiness.
Full answer and how we checked it
PAR-25-149 NINDS U01 renewal eligibility turns on 7 checks: existing eligible U01 award, same approved clinical trial, no new aims, remaining milestone proof, clinical-trial reporting, cooperative-agreement oversight, and due-date readiness.
Who this is for: NINDS clinical trial teams, stroke and neurological-disorder investigators, clinical coordinating centers, trial operations teams, and sponsored-research offices deciding whether PAR-25-149 is the right renewal route.
Data note: This guide uses the official NIH PAR-25-149 NOFO, Grants.gov listing 356870, NIH clinical-trial policy pages, and Grantsights award-data signals checked on May 19, 2026. Due dates, review criteria, and NIH RePORTER awards were rechecked on October 9, 2026.
In this guide
- 7 PAR-25-149 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- What NIH Doesn't Tell You
- 6 Evidence Assets That Make This Renewal Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day NINDS U01 Renewal Readiness Plan
- Which Parent Awards Qualify
- What Reviewers Weigh in a Renewal
- Budget, Timeline, and Required Plan Details
- Renewals Funded So Far
- 6 Final Research Checks Before Submission
- 4 Decision Questions Before Writing
- 3 Last-Mile Checks For Trial Teams
- Sources
Quick Facts
- Agency
- HHS
- Deadline
- Nov 5, 2027
- Status
- Open
Assistance Listing 93.853: all awards
Source: USASpending.gov FY2024These figures cover all National Institutes of Health awards under Assistance Listing 93.853, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.
- Total Awards (FY2024, whole listing)
- 7,925
- Avg Award (whole listing)
- $2,429,698
- Median Award (whole listing)
- $1,670,376
- Total Funding (FY2024, whole listing)
- $1.8B
- YoY Funding Trend
- +0.3%
Data last verified: May 19, 2026
According to NIH PAR-25-149 (opens in a new tab), this limited competition NOFO invites renewal applications from existing NINDS-supported clinical trial cooperative agreement awards that need additional time and resources to complete the clinical trial. NIH lists the activity code as U01 and marks clinical trials as required.
This is not a broad clinical trial funding route. It is a completion route for a narrow set of existing NINDS-supported U01 trials. The first decision is whether the applicant is eligible. The second decision is whether the renewal request is limited to the time and funding needed to finish the already approved trial.
Use this guide with the live Grantsights program record. Then compare NIH grants complete guide, what is a NOFO, NHLBI clinical trial pilot guide, NCI K99 guide, and the Grantsights grant database.
7 PAR-25-149 Eligibility Stop Checks
Within 21 days, run 7 stop checks before writing a renewal.
| Stop check | Strong PAR-25-149 signal | Red flag |
|---|---|---|
| Existing award | Active eligible NINDS-supported U01 trial | No qualifying parent award |
| Trial scope | Same approved clinical trial | New aims or new trial question |
| Need | More time or resources are needed to finish | Request funds for expanded science |
| Milestones | Enrollment, closure, data, analysis, and reporting are concrete | Completion story is vague |
| Oversight | DSMB, IRB, and ClinicalTrials.gov duties are current | Trial governance is behind |
| Budget | Budget matches remaining work | Budget rebuilds the project |
| Timing | Due date and correction window are realistic | Submission is rushed |
Renewal teams can underestimate the "no new aims" line. For this NOFO, that warning is not cosmetic. It can make the application out of scope before reviewers ever score it.
5 Source Facts Applicants Should Know
According to NIH, PAR-25-149 is limited to renewals of existing NINDS-supported clinical trial cooperative agreement awards requiring added time and resources to complete the active trial.
According to NIH, eligible applications are renewals of existing cooperative agreement U01 awards originally submitted under specific NINDS or StrokeNet NOFOs. NIH also says applications with new aims will be out of scope and returned without review.
According to USAspending.gov (opens in a new tab) data, NINDS assistance listing 93.853 had about $1.83B in FY2024 obligations across 7,925 awards active that year.
| Fact | Source-backed read |
|---|---|
| Funding number | PAR-25-149 |
| Activity code | U01 cooperative agreement |
| Clinical trial status | Clinical trials required |
| Next due date | November 5, 2026 |
| Final listed due date | November 5, 2027 (NOFO expires November 6, 2027) |
| Project period | Up to 5 years |
| Live listing | Grants.gov listing 356870 |
What NIH Doesn't Tell You
Within 21 days, answer 4 practical questions. First, this application is about finishing, not restarting. If the team needs a new trial question, a new endpoint, a new population, or a major expansion, PAR-25-149 is probably not the right home.
Second, the application needs a completion narrative that is more operational than aspirational. A trial team with remaining enrollment, data cleaning, final analysis, ClinicalTrials.gov reporting, and manuscript milestones can make a clear case. A team using the renewal to redesign the trial needs a different route.
Third, trial governance matters. The application should show IRB status, DSMB engagement, enrollment by relevant groups, data collection progress, closure plan, and final public-use dataset plan where applicable.
Fourth, scope risk outweighs everything else. The costliest mistake is a renewal package that NIH reads as a new project, because it's returned without review.
6 Evidence Assets That Make This Renewal Stronger
Within 21 days, build 6 evidence assets. Asset 1 is the parent-award proof memo. List the original U01 award, parent NOFO, trial title, original approved aims, current project period, and remaining work.
Asset 2 is the no-new-aims map. Put every requested activity next to the original approved trial aim. Anything that does not map should be removed or routed elsewhere.
Asset 3 is the milestone table. Include enrollment remaining, participant follow-up, data collection, primary endpoint analysis, secondary endpoint analysis, final report, publications, ClinicalTrials.gov results reporting, and dataset submission.
Asset 4 is the budget-to-completion crosswalk. Tie every requested dollar to remaining trial tasks, clinical sites, coordinating centers, data systems, monitoring, analysis, and reporting.
Asset 5 is the oversight packet. Include DSMB, IRB, protocol change history, safety monitoring, study closure, data management, and reporting status.
Asset 6 is the route memo. Compare PAR-25-149 with a new U01, R01, R34, UG3/UH3, administrative supplement, closeout plan, or non-NINDS route.
5 Route Choices Before Drafting
Within 21 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-149 | Existing eligible U01 trial needs completion funds | Renewal route fits |
| New U01 | The trial question or design changes materially | New project route may fit |
| R34 | Planning work is still needed | Planning route may fit |
| Administrative supplement | Need is narrow and in-scope | Smaller route may fit |
| Closeout without renewal | Remaining work can be finished without new funds | Lowest route risk |
Warning: if the request cannot be explained as "finish the approved trial," don't start with PAR-25-149. The strongest renewal story is narrow, disciplined, and almost boring: same approved trial, remaining work, credible milestone plan.
6 Bad-Fit Signals
First, the parent award is not eligible. Second, the application introduces new aims. Third, the trial needs redesign rather than completion.
Fourth, enrollment is behind with no credible recovery plan. Fifth, DSMB, IRB, or reporting duties are not current. Sixth, the budget asks for work that is not tied to remaining trial milestones.
Those signals don't mean the science is weak. They mean the renewal path may be unsafe. A trial with clean DSMB minutes, current enrollment tables, and a final analysis plan is in a different position from one that still needs a major endpoint change.
21-Day NINDS U01 Renewal Readiness Plan
Days 1 through 3 should confirm parent-award eligibility, active trial status, original aims, and due date. Days 4 through 7 should build the no-new-aims map and remaining-milestone table.
Days 8 through 12 should complete the budget-to-completion crosswalk and oversight packet. Days 13 through 16 should compare PAR-25-149 with new U01, R34, supplement, and closeout options. Days 17 through 21 should complete NIH application checks, clinical-trial reporting checks, institutional review, and final scope review.
Which Parent Awards Qualify
PAR-25-149 names the parent NOFOs. Eligibility is limited to institutions holding an existing NINDS U01 originally submitted under one of these 5:
| Parent NOFO | Program |
|---|---|
| PAR-17-102 | NINDS Efficacy Clinical Trials (U01) |
| PAR-18-422 | NINDS Efficacy Clinical Trials (U01 Clinical Trial Required) |
| PAR-14-220 | NIH StrokeNet Clinical Trials and Biomarker Studies (U01) |
| PAR-17-274 | NIH StrokeNet Clinical Trials and Biomarker Studies (U01) |
| PAR-18-561 | NIH StrokeNet Clinical Trials and Biomarker Studies (U01 Clinical Trial Optional) |
A U01 funded under any other NOFO isn't eligible, however close the science. NINDS also encourages teams to discuss the renewal with program staff and "seek approval to submit as necessary" before applying. Only renewal and resubmission application types are accepted, and foreign organizations can't apply.
What Reviewers Weigh in a Renewal
The NOFO adds renewal-specific questions on top of standard NIH review. Reviewers are told to check that:
- Equipoise still exists in the medical and patient communities, and the trial can still change clinical practice.
- New evidence since the first award still supports the rationale.
- Adequate progress was made in the first funding cycle, and the problems that stopped completion won't carry into the second.
- Fixes are working. Strategies such as adding or dropping enrollment centers should be described, with evidence they've helped if already in place.
- Design changes don't undercut statistical power.
- The eligible population is still available and revised recruitment timelines are feasible.
- Infrastructure can finish enrollment, follow the protocol, and move data on time.
That list is a blunt read of why trials end up here. A renewal that explains a recruitment shortfall without showing what changed at the sites will score poorly.
Budget, Timeline, and Required Plan Details
Budgets aren't capped, but they must "reflect the actual needs" of finishing the trial, and the maximum project period is 5 years. The NOFO also requires:
- All study-related costs to complete the trial, with separate itemized budgets for each subcontract, collaborating center, or core.
- Any industry or other third-party support spelled out in the budget justification. If that support stops and the trial can't continue, NINDS may ask for a close-out plan.
- A site survey table in the recruitment plan, with one row per clinical site and columns such as patients seen in the past 12 months, how many look eligible, and experience enrolling participants with limited English proficiency.
- A timeline that finishes every trial activity within 5 years, with milestones for remaining enrollment, study closure, data collection, endpoint analyses, final report, publication, ClinicalTrials.gov results, and the final public-use dataset for NINDS.
- Optional IRB communications (up to 5 pages) and FDA communications (up to 10 pages, with a 1-page summary).
After award, an NINDS Project Scientist sets milestones with the team. Missing them can mean reduced funding or early termination.
Renewals Funded So Far
According to NIH RePORTER (opens in a new tab) records pulled October 9, 2026, NINDS had funded 2 renewals under PAR-25-149, both in FY2026 and both large multi-site phase 3 trials:
| Award | Institution | Trial | FY2026 award | Project end |
|---|---|---|---|---|
| 2U01NS099046-06 | University of Michigan | BOOST-3, brain oxygen optimization in severe traumatic brain injury | $3,858,572 | February 2029 |
| 2U01NS113851-06 | Northwestern University | SPARX3, phase 3 exercise trial in Parkinson disease | $3,136,413 | August 2030 |
Grantsights checked those records against the NOFO's eligibility rules: both are year-6 renewals of U01s that began in 2018 and 2019, when the parent NOFOs listed above were active. For example, Michigan received $3,858,572 in March 2026 for BOOST-3, plus 4 smaller supplements under the same NOFO. The takeaway is that this route funds mature, late-stage trials that need a second cycle, not early or pilot studies.
6 Final Research Checks Before Submission
Within 21 days, finish 6 final checks. Check 1 is the NIH PAR-25-149 NOFO (opens in a new tab). Check 2 is NIH application-guide compliance. Check 3 is parent-award eligibility. Check 4 is no-new-aims review. Check 5 is trial oversight and ClinicalTrials.gov reporting. Check 6 is due-date readiness.
You're ready when the renewal can explain the remaining trial work, the need for more time or funding, and the lack of new aims in 3 direct paragraphs.
4 Decision Questions Before Writing
Within 21 days, ask 4 decision questions. Question 1: "Do you have an eligible existing NINDS U01 clinical trial award?" Question 2: "Are you only asking for what is needed to complete the approved trial?" Question 3: "Can every task map to the original aims?" Question 4: "Are DSMB, IRB, enrollment, and reporting duties current?"
If question 3 fails, pick a different route before the team spends weeks writing.
3 Last-Mile Checks For Trial Teams
Within 21 days, run 3 last-mile checks. Check 1 is eligibility proof. Check 2 is no-new-aims proof. Check 3 is completion proof.
If those checks are weak, contact NINDS before finalizing the application. A final note for applicants: write the renewal fit sentence before the Specific Aims page. In 2 sentences, state the parent award, remaining approved trial work, requested time or funding, and why no new aims are being proposed.
Sources
Largest awards active in FY2024
One row per recipient, its largest award | 7,925 Assistance Listing records | Avg: $2.4M
University of California, Los Angeles
CA
President and Fellows of Harvard College
MA
Use the visible recipient rows as free source context
This program has no reviewed paid report today.
No reviewed paid report is currently offered for this program. The visible source rows remain free.
Frequently Asked Questions
What does PAR-25-149 support?
It supports renewal applications from existing NINDS-supported U01 clinical trial cooperative agreement awards that need additional time and resources to finish the approved clinical trial.
Is a clinical trial required?
Yes. NIH lists the activity as U01 Clinical Trials Required.
Can applicants add new aims?
No. NIH says applications that include new aims will be considered out of scope and returned without review.
What are the remaining due dates?
PAR-25-149 lists November 5, 2026, March 5, 2027, July 5, 2027, and November 5, 2027. The NOFO expires November 6, 2027.
Who should skip this route?
Skip it if the applicant does not already have an eligible NINDS-supported U01 clinical trial award or if the plan changes the approved trial rather than completing it.
Last updated October 9, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-135 NCI K99 eligibility Guide
PAR 25 135 NCI K99 guide: 7 checks for eligibility, deadlines, budget, evidence, route fit, review criteria, and the 2027 K award changes.
NCI K99 Clinical Trial Required Guide
PAR-25-313 guide: NCI K99/R00 clinical trial required eligibility, postdoc limits, K99 to R00 transition, salary, and route checks.
PAR-25-032 NHLBI R34 pilot eligibility Guide
PAR-25-032 NHLBI R34: $450,000 direct over 3 years, new due dates through March 16, 2027, and what 151 past pilots led to.
NIH Clinical Center U01 Eligibility Guide
NIH Clinical Center U01 guide: 8 checks for PAR-26-116, intramural collaboration, Clinical Center use, $500K direct-cost cap, and LOS prep.
PA-25-304: NIH Parent R21 (Clinical Trial Not Allowed)
PA-25-304 is NIH's parent R21 with no clinical trial: $275,000 over 2 years, 21 institutes. Next due Nov 16, 2026 and Feb 16, 2027; expires Jan 8, 2028.
NIH ALS Expanded Access U01 Eligibility
NIH ALS expanded access U01 guide for RFA-NS-26-001, trial-site eligibility, small-business IND sponsor rules, and route fit.